Patents Assigned to ZymoGenetics, Inc.
  • Human cytokine receptor
    Patent number: 8101381
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: January 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Soluble IL-17RCx4 and fusion proteins thereof
    Patent number: 8093355
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: January 10, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Rolf E. Kuestner, Zeren Gao, Steven D. Levin, Mark W. Rixon
  • Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
    Patent number: 8084426
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 27, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Soluble IL-17RA/RC fusion proteins and related methods
    Patent number: 8084231
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: December 27, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Mark W. Rixon, Gao Zeren
  • Trimerizing polypeptides
    Patent number: 8084230
    Abstract: The present invention relates to a method of preparing a trimeric protein comprising culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a ZymoZipper (ZZ) domain and a heterologous protein. In one embodiment, the heterologous protein is a membrane protein, the portion of the heterologous protein that included in the fusion protein is the extracellular domain of that protein, and the resulting fusion protein is soluble. In another embodiment of the present invention, the ZZ domain is derived from the transmembrane (TM) subunit of a virus envelope protein or another heptad repeat containing gene of a virus genome. The method can be used to produced homo- and hetero-trimeric proteins. The present invention also encompasses DNA molecules, expression vectors, and host cells used in the present method and fusion proteins produced by the present method.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 27, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Margaret Dow Moore, Brian A. Fox
  • Stabilized thrombin compositions
    Patent number: 8071090
    Abstract: Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. The compositions are stable when stored at 2° C.-8° C. for four weeks or more.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: December 6, 2011
    Assignee: Zymogenetics, Inc.
    Inventors: Richard I. Senderoff, Shan Jiang
  • Method for activating prethrombin-1
    Patent number: 8062876
    Abstract: Methods for converting prethrombin-1 to thrombin are disclosed. An aqueous solution of prethrombin-1 is applied to oscutarin-C immobilized on a solid support so as to provide from 500 mg to 4000 mg of prethrombin-1 per mL of the solid support and a contact time between the prethrombin-1 and the oscutarin-C of from 1.8 to 3.5 minutes. The resulting active thrombin may be captured on an ion exchange chromatography medium or an affinity chromatography medium.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 22, 2011
    Assignee: Zymogenetics, Inc.
    Inventors: Robert W. Mallett, Christopher J. Stenland, Jonathon C. Boone, John W. Forstrom, Karen S. De Jongh
  • Growth factor homolog ZVEGF3
    Patent number: 8052976
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: November 8, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberty E. Shoemaker, Debra G. Gilbertson, James W. West
  • Method of suppressing or reducing IL-TIF-induced inflammation, or treating associated conditions thereof, using Zcytor16
    Patent number: 8034784
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16” and uses thereof.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: October 11, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Methods of determining dose of IL-31 agonist to treat pulmonary inflammation
    Patent number: 8029775
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: October 4, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • METHODS FOR USING TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20110229473
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: May 11, 2011
    Publication date: September 22, 2011
    Applicant: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Cytokine zalpha11 ligand antibodies and methods of use
    Patent number: 8017343
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: September 13, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Methods of using IL-31 monoclonal antibodies to reduce inflammation
    Patent number: 8017122
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: September 13, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Antibodies to human zcytor17 ligand
    Patent number: 8013124
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: September 6, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Angela K. Hammond, Julia E. Novak
  • Method for treating inflammation
    Patent number: 8003104
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: August 23, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
  • Cytokine zalpha11 ligand antibodies
    Patent number: 7998468
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 16, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • MURINE ZCYTOR17 LIGAND POLYNUCLEOTIDES
    Publication number: 20110196128
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: April 8, 2010
    Publication date: August 11, 2011
    Applicant: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E. Kuestner
  • SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20110177083
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
    Type: Application
    Filed: January 27, 2011
    Publication date: July 21, 2011
    Applicant: Zymogenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Steven D. Levin, Rolf E. Kuestner, Zeren Gao, Stephen R. Jaspers, Janine Bilsborough
  • MEDICAL DEVICES FOR DELIVERING FLUIDS DURING SURGERY AND METHODS FOR THEIR USE
    Publication number: 20110166550
    Abstract: Provided is a surgical applicator and applicator tip configured to attach in fluid communication, for the delivery of beneficial fluids. The applicator tip may also be configured to reversibly attach, in fluid communication, with a pledget. For example, the applicator tip may include male or female threads, and the pledget has threads that are complementary to the thread configuration of the tip. The applicator tip may further comprise at least one fluid transfer lumen for transfer of a fluid from the tip to the pledget. In one embodiment of the invention, the tip includes male threads and the pledget includes a pledget attachment portion. There are also provided methods for connecting the tip to the pledget. In one embodiment, a tip comprising male threads is attached to the pledget, comprising a pledget attachment portion, by tapping or pressing the tip into the pledget attachment portion.
    Type: Application
    Filed: April 27, 2009
    Publication date: July 7, 2011
    Applicant: ZYMOGENETICS, INC.
    Inventors: William Allan Alexander, Paul D. Bishop, Steve R. Carter, Alisa M. Littau
  • Production and purification of IL-29
    Patent number: 7968315
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 28, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Robert M. Dedinsky